Shineco, a China herbal medicine company, announced plans to acquire a 51% stake in Taiwan 's Mayah Biological Holdings. Mayah describes itself as a biotech that focuses on novel chemical and biomedicine products in pre-clinical and clinical stages. Its lead product has completed a Phase II trial, with a second cancer therapy ready to start a Phase II trial, and three other cancer drugs about to enter clinical development. At the moment, the two companies are doing their due diligence, with no guarantee that an actual transaction will take place. More details.... Stock Symbol: (NSDQ: TYHT) Share this with colleagues: // //